Chloro¯uorocarbon (CFC)-containing inhalers for use in the treatment of asthma are to be phased out under the terms of the Montreal Protocol (1). In this multi-centre, randomized, double-blind study, the therapeutic equivalence of two formulations of beclomethasone dipropionate (BDP) containing CFC or non-CFC (HFA134a) propellant, both delivered via the Easibreathe TM (Norton Healthcare Ltd, London, U.K.) inhaler, was determined in 229 asthmatic children. Each child received 100 mg doses of BDP (containing either CFC or HFA propellant) twice daily for 12 weeks.
Introduction
Beclomethasone dipropionate (BDP) is a corticosteroid indicated for the prophylactic management of asthma. Although the action of BDP is anti-in¯ammatory (2) and the exact mechanism of corticosteroid action within the lung is not fully understood, treatment with BDP reduces bronchial mucosal in¯ammation with consequent reduction of bronchial oedema and mucus secretion.
Treatment with BDP for the prophylactic management of asthma is invariably by inhalation. This is commonly via a pressurized metered-dose inhaler (pMDI). Currently, most pMDIs utilize a conventional chloro¯uorocarbon (CFC) propellant to form an aerosol of BDP for inhalation. Under the terms of the Montreal Protocol (1) , use of such CFC propellants is to be phased out due to their ozone depleting potential.
A CFC-free formulation of BDP has been developed (Norton Healthcare Ltd.) which utilizes 1,1,1,2-tetra¯uor-oethane, a hydro¯uorocarbon propellant (commonly known as HFA-134a) and which is predicted to have minimal ozone depleting potential. The pharmacology and toxicology of this HFA molecule have been studied extensively by the International Pharmaceutical Aerosol Consortium for Toxicology Testing (IPACT-1). Further testing by pharmaceutical companies has shown that this propellant is free from any serious toxicity. Single-and multi-dose studies of HFA-134a in healthy humans have shown that it is well tolerated at dose levels well above those required for use in inhalation devices (3±5).
Other BDP products containing HFA-134a have recently been evaluated (6±8). These studies have shown that in combination with HFA-134a, beclomethasone dipropionate is as safe and as eective as the currently available CFC-containing products (6) . Although a dose switch from CFC to CFC-free products is a desirable course of action, it has been suggested that due to the ®ne particle characteristics of the new formulations, it may be possible to reduce the eective dose by up to 50% (7, 8) . Whilst dose reduction has obvious clinical bene®ts, any such reductions must be closely supervised and should be carefully balanced against potential confusion that may be caused to the patient. The BDP formulation in this current study has been developed to allow a seamless dose for dose transition from CFC to CFC-free inhaler.
A novel breath-operated inhaler device (Easibreathe TM ) has been speci®cally designed to overcome the co-ordination problems patients experience when using standard pMDIs.
The aim of this study was to assess therapeutic equivalence and comparable safety of BDP-HFA and BDP-CFC both via Easibreathe TM inhaler when administered to asthmatic children.
Patients and methods

PATIENTS
Asthmatic children aged 7±12 years (inclusive) were eligible for the study. Patients were recruited from 44 General Practice and Hospital sites in the U.K., South Africa, the Czech Republic, Yugoslavia and Hungary. All patients and their parent/guardian gave written informed consent to the child's participation. At baseline all patients were required to demonstrate a forced expiratory volume in 1 sec (FEV 1 ) of at least 60% of that predicted for their height and gender, and a reversibility of at least 10% in FEV 1 following inhalation of a standard 200 mg dose of salbutamol from a pMDI. Patients with a documented reversibility in FEV 1 of !10% recorded in the previous 12 months were also allowed to participate. Each patient was currently receiving an inhaled bronchodilator b 2 -agonist and may also have been receiving sodium cromoglycate or nedocromil sodium (provided the dose remained constant throughout the study). Patients currently receiving inhaled corticosteroids or oral corticosteroids, or patients with unstable asthma, were excluded from the study. Patients with any signi®cant medical or psychological conditions were also excluded.
Study design
This investigation was a randomized, double-blind, parallel group study. The patents were randomized in ascending numerical order at each site according to a predetermined random code generated by the Statwood Partnership. Eligible patients entered a 2 week placebo run-in period, during which they were instructed to take one pu twice daily from a CFC placebo Easibreathe TM inhaler. Patients used a mini-Wright Peak Flow Meter TM (Clement Clarke International Ltd., U.K.), to record twice daily PEF readings throughout the study. In addition patients also recorded daily use of relief bronchodilator and daytime and night-time asthma symptoms. At the end of the run-in period, each patient was required to have used relief bronchodilator (two pus or more) on at least 3 days out of the last seven of the run-in period. Eligible patients were then randomized to receive either BDP-CFC or BDP-HFA at a dose of 100 mg twice daily via the Easibreathe TM inhaler for the next 12 weeks. Data recorded on diary cards were the same as for the run-in period. Each patient reattended the clinic at 1, 4, 8 and 12 weeks after randomization. At each visit assessments of lung function and emergent adverse events were made. Twenty four hour urinary cortisol measurements were made at the start and end of treatment in a sub-population (*20%) of the patients. Oropharyngeal swabs for Candida albicans were taken at the start and end of the study in all patients and where clinically indicated on symptomatic grounds throughout.
METHODS
Ethics committee approval was obtained as appropriate for each participating centre.
Measurement of lung function
Prior to taking any inhaled medication, patients were instructed to make three measurements of PEF on rising each morning, and again each evening before going to bed, using a mini-Wright Peak Flow Meter TM (Clement Clarke International Ltd., Harlow, U.K.). All three recordings of PEF on each occasion were documented by the patients on diary cards. Spirometric assessments were made by the investigator at each clinic visit using a calibrated Micro spirometer TM (Micro Medical Ltd., Rochester, U.K.). Local reference values were used.
Diary card data
Use of relief medication and symptom scores also were recorded twice daily. Patient's assessments of cough, wheeze and overall symptoms were recorded using 4-point (0±3) rating scales.
Safety assessments
These comprised clinical adverse events, 24 h urinary cortisol assessments (in approximately 20% of the patients) and presence of C. albicans on oropharyngeal swabs.
STATISTICAL METHODS
Sample size
To detect a mean dierence of 25 l min 71 in morning PEF (10% of the expected level of 250 l min
71
) between treatments using a two-sided 95% con®dence interval, 105 patients per treatment group were needed. This estimate assumed a standard deviation of 50 l/min 71 for each group and 90% power. To accommodate for dropouts and unevaluable patients, 130 patients were selected to be randomized to each treatment group.
Efficacy analysis
Mean morning PEF was calculated from the diary cards for weeks 11 and 12 of treatment. The data were subjected to an analysis of covariance to allow for the eect of treatment, using baseline measurements as covariate. Baseline was taken to be the mean value over the last week before randomization. A test for parallel slopes was carried out by looking at the treatment by baseline interaction. The student's t-test residuals were examined for normality by plotting the ranked values against their normal scores and for constant variance by plotting them against the ®tted values. The ratio (expressed as percentage) of the two treatments (HFA/CFC) was estimated and 95% con®dence intervals constructed. All other lung function parameters were analysed in the same manner. For all outcome variables, equivalence was declared when the 95% con®dence interval for the ratio of treatment means relative to the CFC mean was completely contained within the interval (90%, 110%).
Symptom scores were analysed using Wilcoxon rank sums test. An estimate of the treatment dierence, together with 95% con®dence intervals was calculated using the Hodges±Lehmann method. No adjustment was made for baseline values.
Results
A total of 229 patients were recruited into the study of whom 199 provided evaluable data. Seven patients were withdrawn during the course of the study (four from the BDP-HFA group and three from the BDP-CFC group). Of these seven, two patients in each group were withdrawn for violation of the study protocol, two in the BDP-HFA group were withdrawn for unspeci®ed reasons and one patient in the BDP-CFC group was withdrawn due to an exacerbation of asthma requiring hospitalisation. In addition 22 patients were excluded from the per-protocol analysis for violations of the study protocol and a further patient was excluded from the analysis as they had received less than 10 weeks of study medication. The ecacy analyses were carried out on the per-protocol sample of 199 patients (103 BDP-HFA and 96 BDP-CFC). Demographic details are given in Table 1 .
The two treatment groups in the per-protocol analysis were well matched with respect to baseline lung function.
EFFICACY
Mean morning and evening PEF in both treatment groups increased over the study period and had reached a peak by week 10. For the per-protocol population these increases were statistically signi®cant (P50Á001) at all post-treatment time points (Fig. 1) . The overall improvements in mean morning PEF were 41 l min 71 and 34 l min 71 for the BDP-HFA and BDP-CFC groups respectively. For mean evening PEF the corresponding values were 38 l min 71 and 32 l min
71
. The estimated treatment dierence for mean morning PEF was 2Á6% and the two treatments are thus equivalent (Table 2) . Similarly equivalent results were obtained for mean evening PEF with the estimated treatment dierence being 2Á1%. Results for all of the other lung function parameters were also equivalent. The only exception to this was mean daily variability in PEF which decreased from 21±16% in the BDP-HFA group and from 22±16% in the BDP-CFC group. Compared to baseline there were marked, signi®cant decreases in the proportion of patients reporting daytime and night-time symptoms in both of the treatment groups and also in the proportion of patients using relief medication (Fig. 2) . This is indicative of an overall improvement in asthma control for both treatments. baseline and at the end of study 13% of patients in the BDP-HFA group and 9% in the BDP-CFC group had positive cultures.
TWENTY FOUR HOUR URINARY CORTISOL
Mean baseline 24 h urinary cortisol values was assessed in 43/229 (19%) of patients and were comparable for both treatment groups (data from patients with only one measurement either pre-or post-study were excluded from this calculation). Mean baseline values were 129 nmol 24 h 71 for BDP-HFA (n=24) and 150 nmol 24 h 71 for BDP-CFC (n=19). The mean post-treatment values were 125 nmol 24 h 71 and 121 nmol 24 h 71 respectively. Individual patient data are presented in Fig. 3 . The mean change for the BDP-HFA group was 74Á6 nmol 24 h 71 and for the BDP-CFC group the mean change was 728Á5 nmol 24 h 71 .
Discussion
The introduction of new CFC-free propellants for asthma inhalers has presented healthcare professionals and the pharmaceutical industry with a number of unique challenges. Two main challenges are the determination of therapeutic equivalence between old and new products, and evolving strategies to manage the change over with respect to dosing levels and patient education. In 1995 the British Association for Lung Research issued guidelines for the determination of equivalence for inhaled medication (9), but these did not de®ne therapeutic equivalence. A more recent set of guidelines published by the Canadian Thoracic Society (10) gives detailed advice on the design and conduct of appropriate studies, but again falls short of a de®nition of therapeutic equivalence. This current study pre-dated publication of the Canadian report, but has included many of the recommendations that were proposed therein.
When designing studies to demonstrate therapeutic equivalence between asthma treatments it is important to show comparable improvement in asthma control with each, especially in patients who are steroid-naõÈ ve, as here. The study included a large number of patients with well de®ned asthma. Patients were thoroughly trained in inhaler use, the end points were consistent with the recommendations for establishing equivalence and the data were analysed to present 95% con®dence intervals with a tight de®nition of equivalence.
This study has demonstrated that the newly formulated BDP-HFA inhaler is therapeutically equivalent to the existing BDP-CFC inhaler at a dose of 100 mg b. con®dence intervals being completely within the range of 90±110%. The two treatments produced equivalent levels of ecacy in terms of eect on lung function and symptom control and had equivalent tolerability pro®les. There was no evidence of any marked eects of either treatment on HPA function as assessed by 24 h urinary cortisol measurements, as might be expected at this dosage level for inhaled BDP. Mean changes in this parameter were greater if anything in the BDP-CFC group, at the end of the study.
For the primary ecacy endpoint, mean morning PEF, the estimated treatment dierence was only 2Á6%, which represents a dierence in PEF between treatments of 8Á5 l min 71 . The upper 95% Cl limit for this parameter showed a dierence of 6Á2%, representing a worst case dierence between treatments of 20 l min 71 . Both formulations produced similar incidences of adverse events and these events were entirely consistent with those expected for a population of the type enrolled into this study.
Based on these results it appears possible to switch from a CFC to a CFC-free BDP formulation on a dose for dose basis. This is an important consideration which would facilitate a seamless transition to the new CFC-free inhalers for both clinicians and patients. Some recent studies have suggested that it may be possible to reduce the dose of corticosteroid by up to 50% when switching patients from BDP-CFC to BDP-HFA (7, 8) . This has been based upon the principle that, although the site of action for inhaled corticosteroids is not yet fully known, there is a greater ®ne particle deposition and penetration in the lung of BDP-HFA than BDP-CFC and that this correlates with enhanced ecacy. It may be argued conversely that an increase in ®ne particle penetration may lead to an increase in systemic absorption and subsequently an increase in adverse eects; further work is required in this respect. However, it is important to note that these dose reduction studies have not included direct comparisons at the same dose levels for BDP-CFC and BDP-HFA. In addition, results of these studies have been contradicted by a further study with the same formulation of BDP-HFA which showed a dose for dose equivalence (6) . Two recent studies in adults (11) using the same formulation of BDP-HFA that was used in this current study also showed a dose for dose equivalence at both low and high doses further supporting the ®ndings presented in this study. It is possible that the lack of a clinical dierence between the HFA and CFC formulations may be a result of the relatively¯at dose response curve seen with corticosteroids, although the fact that some studies have shown a clinical dierence contradicts this.
In summary this study has shown that paediatric patients may be switched from currently available BDP-CFC inhalers to the new BDP-HFA inhalers at the same dose without loss of ecacy or asthma control, and with no changes in tolerability. In addition this study has also con®rmed the eectiveness of the Easibreathe TM inhaler in paediatric patients irrespective of the type of propellant used to deliver BDP. 
